Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Malignant Melanoma

  Free Subscription

Articles published in J Immunol

Retrieve available abstracts of 13 articles:
HTML format
Text format

Single Articles

    September 2018
  1. BADAMCHI-ZADEH A, Moynihan KD, Larocca RA, Aid M, et al
    Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.
    J Immunol. 2018 Sep 24. pii: jimmunol.1800885. doi: 10.4049/jimmunol.1800885.
    PubMed     Text format     Abstract available

    August 2018
  2. VIGNERON N, Ferrari V, Van den Eynde BJ, Cresswell P, et al
    Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.
    J Immunol. 2018 Aug 22. pii: jimmunol.1701479. doi: 10.4049/jimmunol.1701479.
    PubMed     Text format     Abstract available

    April 2018
  3. GILFILLAN CB, Kuhn S, Baey C, Hyde EJ, et al
    Clec9A(+) Dendritic Cells Are Not Essential for Antitumor CD8(+) T Cell Responses Induced by Poly I:C Immunotherapy.
    J Immunol. 2018;200:2978-2986.
    PubMed     Text format     Abstract available

  4. RIUS C, Attaf M, Tungatt K, Bianchi V, et al
    Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.
    J Immunol. 2018;200:2263-2279.
    PubMed     Text format     Abstract available

    March 2018
  5. GODING SR, Wilson KA, Rosinsky C, Antony PA, et al
    PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4(+) T Cell Adoptive Immunotherapy.
    J Immunol. 2018 Mar 30. pii: jimmunol.1701617. doi: 10.4049/jimmunol.1701617.
    PubMed     Text format     Abstract available

    February 2018
  6. MITTAL P, Abblett R, Ryan JM, Hagymasi AT, et al
    An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
    J Immunol. 2018;200:1513-1526.
    PubMed     Text format     Abstract available

    October 2017
  7. DING Q, Mohib K, Kuchroo VK, Rothstein DM, et al
    TIM-4 Identifies IFN-gamma-Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection.
    J Immunol. 2017;199:2585-2595.
    PubMed     Text format     Abstract available

    May 2017
  8. ZILIO S, Vella JL, De la Fuente AC, Daftarian PM, et al
    4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells.
    J Immunol. 2017;198:4166-4177.
    PubMed     Text format     Abstract available

    February 2017
  9. ERKES DA, Smith CJ, Wilski NA, Caldeira-Dantas S, et al
    Virus-Specific CD8+ T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression.
    J Immunol. 2017 Feb 15. pii: 1601064. doi: 10.4049/jimmunol.1601064.
    PubMed     Text format     Abstract available

    January 2017
  10. RAKHMILEVICH AL, Felder M, Lever L, Slowinski J, et al
    Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
    J Immunol. 2017 Jan 6. pii: 1601255. doi: 10.4049/jimmunol.1601255.
    PubMed     Text format     Abstract available

  11. BALLY AP, Tang Y, Lee JT, Barwick BG, et al
    Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory.
    J Immunol. 2017;198:205-217.
    PubMed     Text format     Abstract available

    December 2016
  12. NASTI TH, Cochran JB, Vachhani RV, McKay K, et al
    IL-23 Inhibits Melanoma Development by Augmenting DNA Repair and Modulating T Cell Subpopulations.
    J Immunol. 2016 Dec 21. pii: 1601455. doi: 10.4049/jimmunol.1601455.
    PubMed     Text format     Abstract available

  13. WISTUBA-HAMPRECHT K, Martens A, Weide B, Teng KW, et al
    Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients.
    J Immunol. 2016 Dec 16. pii: 1600875.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.